Your browser is no longer supported. Please, upgrade your browser.
Alterity Therapeutics Limited
Index- P/E- EPS (ttm)-0.70 Insider Own18.70% Shs Outstand22.06M Perf Week-9.66%
Market Cap45.19M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float15.43M Perf Month-7.09%
Income-12.70M PEG- EPS next Q- Inst Own3.60% Short Float1.44% Perf Quarter-31.41%
Sales0.03M P/S1605.34 EPS this Y25.00% Inst Trans-3.20% Short Ratio0.12 Perf Half Y4.80%
Book/sh1.21 P/B1.08 EPS next Y- ROA-80.20% Target Price- Perf Year95.23%
Cash/sh- P/C- EPS next 5Y- ROE-94.60% 52W Range0.55 - 5.15 Perf YTD-2.24%
Dividend- P/FCF- EPS past 5Y-5.10% ROI- 52W High-74.56% Beta1.62
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin- 52W Low138.18% ATR0.10
Employees12 Current Ratio12.30 Sales Q/Q1.50% Oper. Margin- RSI (14)41.78 Volatility5.97% 7.36%
OptionableNo Debt/Eq0.00 EPS Q/Q34.60% Profit Margin- Rel Volume0.08 Prev Close1.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.86M Price1.31
Recom- SMA20-5.79% SMA50-11.23% SMA200-24.51% Volume142,743 Change3.97%
Apr-29-21 08:30AM  
Apr-21-21 09:25AM  
Feb-26-21 07:45AM  
Feb-09-21 08:53AM  
Jan-07-21 08:00AM  
Dec-21-20 08:30AM  
Dec-09-20 09:46AM  
Nov-16-20 10:42AM  
Oct-26-20 10:03PM  
Aug-05-20 03:10PM  
Aug-04-20 09:07AM  
Aug-03-20 09:33PM  
Jul-30-20 06:49PM  
Jul-01-20 08:12AM  
Jun-29-20 11:14PM  
May-20-20 08:58PM  
Apr-30-20 04:35AM  
Apr-21-20 05:50PM  
Feb-21-20 07:15PM  
Nov-11-19 10:30PM  
Sep-12-19 11:07PM  
Jul-29-19 08:00AM  
Jul-11-19 09:31PM  
May-06-19 08:00AM  
May-03-19 08:00AM  
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.